Trending Stocks Alert: Hi-Crush Partners LP (HCLP), Pacira Pharmaceuticals, Inc. (PCRX)


Hi-Crush Partners LP (HCLP):

Last Trade:

Hi-Crush Partners LP (HCLP) ended its previous trading session at $11.4 with the Loss of -2.56%. The company’s market cap is $1.01 Billion, and the average volume is $1.83 Million. The 52-Week High range of the stock is $16.45, while the 52-week low range is $7.25. The Price to Sales (P/S) of the stock is 1.68, while P/B (Price to Book) stands at 1.29. When we look at the Volatility of the company, Week Volatility is at 4.38% whereas Month Volatility is at 5.28%.

For the ongoing Fiscal Quarter, 10 analysts have an average earnings forecast of $0.63 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $0.52, while the High earnings estimate is $0.76.Comparatively, EPS for the same quarter last year was $0.33.

According to 11 analysts, the Average Revenue Estimate for the current Fiscal quarter is $241.11 Million and the Low Revenue estimate is $213.13 Million, while the High Revenue estimate is $270 Million.

Hi-Crush Partners LP (HCLP) analysts on average have given a price target of $16.7 on HCLP stock.

According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 1.44 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.

Pacira Pharmaceuticals, Inc. (PCRX):

Previous Trade:

Pacira Pharmaceuticals, Inc. (PCRX) shares Jumped 6.88% and ended the day at $35.75. Its 52-week high and low range is between $52.48 and $26.95. The company’s outstanding shares are 42.05 Million. The volume of the company in the last trading session was 1.13 Million. The stock has a market cap of 1.5 Billion. The Stock shows P/E value of 0 and Forward P/E of 32.89.

According to Finviz reported data, The SMA20 of the stock is at 12.53%, SMA50 is 8.96 percent, while SMA200 is -6.9%. The stock is currently has its Return on Assets (ROA) value of -7 Percent. The Return on Investment and Return on Equity (ROE) values are -5.2 percent and -15.8 percent, respectively.

The company’s ATR (Average True Range) is 2.39. The Weekly Volatility is 7.79% and the Monthly Volatility is 8.01%.

When we look at the Analyst Recommendations of the stock, the company has 2.31 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

Pacira Pharmaceuticals, Inc. (PCRX) analysts on average have given a price target of $16.7 on PCRX stock.

Pacira Pharmaceuticals, Inc.’s Average Earnings Estimate for the current quarter is $0.06, according to consensus of 18 analysts. The low EPS estimate is $-0.06, while the high EPS estimate is $0.26.

Average Revenue Estimate of the company for the current Fiscal Quarter is $76.92 Million, according to consensus of 19 analysts. The higher end of the revenue estimate is $82.54 Million and the lower end is $74.68 Million.